Integrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteins

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Zhao, Yuqi ^a,b   Wang, Yanjie ^a   Gao, Yuedong ^a   Li, Gonghua ^a   Huang, Jingfei ^a,c  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c The Collaborative Innovation Center of Yunnan Natural Products and Biological Pharmacy   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLCYSTEINYLTRYPTOPHANYLTRYPTOPHANYLALANYLGLYCYLISOLEUCYLARGINYLGLUTAMINYLGLUTAMYLPHENYLALANINE; ALANYLCYSTEINYLTRYPTOPHANYLTRYPTOPHANYLALANYLGLYCYLISOLEUCYLLYSYLALANYLGLUTAMYLPHENYLALANINE; ALANYLCYSTEINYLTRYPTOPHANYLTRYPTOPHANYLALANYLGLYCYLISOLEUCYLLYSYLGLUTAMINYLALANYLPHENYLALANINE; ALANYLCYSTEINYLTRYPTOPHANYLTRYPTOPHANYLALANYLGLYCYLISOLEUCYLLYSYLGLUTAMINYLGLUTAMYLPHENYLALANINE; ASPARTYLGLUTAMINE; CAPSID PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GLYCYLISOLEUCYLGLYCYLASPARTYLPROPYLVALYLTHREONYLCYSTEINYLLEUCYLLYSYLSERYLGLYCYLALANYLISOLEUCYLALANINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTEGRASE; ISOLEUCYLARGINYLLYSYLALANYLHISTIDYLCYSTEINYLASPARAGINYLISOLEUCYLSERYLARGINYLALANYLASPARTYLTRYPTOPHANYLASPARAGINYLASPARTATE; LEUCYLGLUTAMINYLISOLEUCYLTHREONYLLEUCYLTRYPTOPHAN; MATRIX PROTEIN; NEF PROTEIN; NUCLEOCAPSID PROTEIN; PEPTIDE DERIVATIVE; PROTEIN P6; PROTEINASE; REV PROTEIN; RNA DIRECTED DNA POLYMERASE; SERYLEUCYLEUCYLSERYLSERYLPROLYLGLUTAMINE; SERYLPHENYLALANYLASPARAGINYLLEUCINE; SERYLTYROSYLASPARAGINYLLEUCINE; SERYLTYROSYLGLUTAMYLTRYPTOPHAN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIF PROTEIN; VPR PROTEIN; VPU PROTEIN; EPITOPE;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; BIOLOGY; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVE SITE; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; CATALYTIC DOMAIN; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; EPITOPES; EVOLUTION, MOLECULAR; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 84923052702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117506     Document Type: Article

References (75)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868-871. PMID: 6189183
2. Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, et al. (2013) Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Reviews in Medical Virology 23: 221-240. doi: 10.1002/rmv.1739 PMID: 23444290
3. De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, et al. (1993) Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 270: 2083-2086. PMID: 8147962
4. De Cock KM, Jaffe HW, Curran JW (2012) The evolving epidemiology of HIV/AIDS. Aids 26: 1205-1213. doi: 10.1097/QAD.0b013e328354622a PMID: 22706007
5. Abubakar AA (2012) Distribution of CD4 Lymphocyte Cells Among Apparently Healthy HIV Seropositive and Seronegative Populations. N Am J Med Sci 4: 120-123. doi: 10.4103/1947-2714.93882 PMID: 22454823
6. Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2: a007161. doi: 10.1101/cshperspect.a007161 PMID: 22474613
7. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236. PMID: 14985706
8. Streeck H, D'Souza MP, Littman DR, Crotty S (2013) Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med 19: 143-149. doi: 10.1038/nm.3054 PMID: 23389614
9. Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489. PMID: 7824947
10. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153: 126-138. doi: 10.1016/j.cell.2013.03.018 PMID: 23540694
11. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB (2013) Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis 207 Suppl 2: S49-56. doi: 10.1093/infdis/jit107 PMID: 23687289
12. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 305: 1327-1335. doi: 10.1001/jama.2011.375 PMID: 21467286
13. Brackenridge S, Evans EJ, Toebes M, Goonetilleke N, Liu MK, et al. (2011) An early HIV mutation within an HLA-B∗57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. Journal of Virology 85: 5415-5422. doi: 10.1128/JVI.00238-11 PMID: 21430058
14. Rhee SY, Liu TF, Holmes SP, Shafer RW (2007) HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol 3: e87. PMID: 17500586
15. Morcos F, Pagnani A, Lunt B, Bertolino A, Marks DS, et al. (2011) Direct-coupling analysis of residue coevolution captures native contacts across many protein families. Proceedings of the National Academy of Sciences of the United States of America 108: E1293-E1301. doi: 10.1073/pnas.1111471108 PMID: 22106262
16. Socolich M, Lockless SW, Russ WP, Lee H, Gardner KH, et al. (2005) Evolutionary information for specifying a protein fold. Nature 437: 512-518. PMID: 16177782
17. Sulkowska JI, Morcos F, Weigt M, Hwa T, Onuchic JN (2012) Genomics-aided structure prediction. Proc Natl Acad Sci U S A 109: 10340-10345. doi: 10.1073/pnas.1207864109 PMID: 22691493
18. Wang J, Zhao Y, Wang Y, Huang J (2013) Molecular dynamics simulations and statistical coupling analysis reveal functional coevolution network of oncogenic mutations in the CDKN2A-CDK6 complex. FEBS Lett 587: 136-141. doi: 10.1016/j.febslet.2012.11.001 PMID: 23178718
19. Ackerman SH, Gatti DL (2011) The Contribution of Coevolving Residues to the Stability of KDO8P Synthase. PloS one 6.
20. Frankel AD, Young JAT (1998) HIV-1: Fifteen proteins and an RNA. Annual Review of Biochemistry 67: 1-25. PMID: 9759480
21. Halabi N, Rivoire O, Leibler S, Ranganathan R (2009) Protein Sectors: Evolutionary Units of Three-Dimensional Structure. Cell 138: 774-786. doi: 10.1016/j.cell.2009.07.038 PMID: 19703402
22. McLaughlin RN, Poelwijk FJ, Raman A, Gosal WS, Ranganathan R (2012) The spatial architecture of protein function and adaptation. Nature 491: 138-U163. doi: 10.1038/nature11500 PMID: 23041932
23. Ding JP, Das K, Hsiou Y, Sarafianos SG, Clark AD, et al. (1998) Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 angstrom resolution. Journal of Molecular Biology 284: 1095-1111. PMID: 9837729
24. Sarafianos SG, Das K, Tantillo C, Clark AD, Ding J, et al. (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA: DNA. Embo Journal 20: 1449-1461. PMID: 11250910
25. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, et al. (2000) Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8: 1329-1339. PMID: 11188697
26. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. Journal of Computational Chemistry 26: 1781-1802. PMID: 16222654
27. Sackett K, Wexler-Cohen Y, Shai Y (2006) Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. Journal of Biological Chemistry 281: 21755-21762. PMID: 16751188
28. Shafer RW (2006) Rationale and uses of a public HIV drug-resistance database. Journal of Infectious Diseases 194: S51-S58. PMID: 16921473
29. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, et al. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids 21: 215-223. PMID: 17197813
30. Yu XW, Lu L, Cai LF, Tong P, Tan SY, et al. (2012) Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket. Journal of Virology 86: 589-593. doi: 10.1128/JVI.05066-11 PMID: 22013063
31. Qureshi A, Thakur N, Kumar M (2013) HIPdb: A Database of Experimentally Validated HIV Inhibiting Peptides. Plos One 8. doi: 10.1371/journal.pone.0082806 PMID: 24482673
32. Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, et al. (2004) Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase. Biochemistry 43: 13097-13105. PMID: 15476403
33. Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR (1998) Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry 37: 2105-2110. PMID: 9485357
34. Liao HX, Lynch R, Zhou TQ, Gao F, Alam SM, et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469-+. doi: 10.1038/nature12053 PMID: 23552890
35. Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, et al. (2013) Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells. PloS one 8.
36. Echegoyen L (2011) Modern Physical Organic Chemistry. Journal of Physical Organic Chemistry 24: 743-743.
37. He YX, Liu SW, Jing WG, Lu H, Cai DM, et al. (2007) Conserved residue Lys(574) in the cavity of HIV-1 gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. Journal of Biological Chemistry 282: 25631-25639. PMID: 17616522
38. Hinkley T, Martins J, Chappey C, Haddad M, Stawiski E, et al. (2011) A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nature Genetics 43: 487-+. doi: 10.1038/ng.795 PMID: 21441930
39. Sluis-Cremer N, Arion D, Kaushik N, Lim H, Parniak MA (2000) Mutational analysis of Lys(65) of HIV-1 reverse transcriptase. Biochemical Journal 348: 77-82. PMID: 10794716
40. Cortines JR, Monroe EB, Kang S, Prevelige PE (2011) A Retroviral Chimeric Capsid Protein Reveals the Role of the N-Terminal beta-Hairpin in Mature Core Assembly. Journal of Molecular Biology 410: 641-652. doi: 10.1016/j.jmb.2011.03.052 PMID: 21762805
41. Tan QX, Zhu Y, Li J, Chen ZX, Han GW, et al. (2013) Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex. Science 341: 1387-1390. doi: 10.1126/science.1241475 PMID: 24030490
42. Desormeaux A, Coutu M, Medjahed H, Pacheco B, Herschhorn A, et al. (2013) The Highly Conserved Layer-3 Component of the HIV-1 gp120 Inner Domain Is Critical for CD4-Required Conformational Transitions. Journal of Virology 87: 2549-2562. doi: 10.1128/JVI.03104-12 PMID: 23255784
43. Esposito F, Kharlamova T, Distinto S, Zinzula L, Cheng YC, et al. (2011) Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. Febs Journal 278: 1444-1457. doi: 10.1111/j.1742-4658.2011.08057.x PMID: 21348941
44. Suel GM, Lockless SW, Wall MA, Ranganathan R (2003) Evolutionarily conserved networks of residues mediate allosteric communication in proteins. Nature Structural Biology 10: 59-69. PMID: 12483203
45. Novinec M, Korenc M, Caflisch A, Ranganathan R, Lenarcic B, et al. (2014) A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods. Nat Commun 5: 3287. doi: 10.1038/ncomms4287 PMID: 24518821
46. Clavel F, Hance AJ (2004) Medical progress: HIV drug resistance. New England Journal of Medicine 350: 1023-1035. PMID: 14999114
47. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, et al. (2011) CD4 and CD8 T Cell Immune Activation during Chronic HIV Infection: Roles of Homeostasis, HIV, Type I IFN, and IL-7. Journal of Immunology 186: 2106-2116. doi: 10.4049/jimmunol.1002000 PMID: 21257970
48. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, et al. (1997) Vigorous HIV-1-specific CD4(+) T cell responses associated with control of viremia. Science 278: 1447-1450. PMID: 9367954
49. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, et al. (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523-526. PMID: 11029005
50. Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Iyengar S, et al. (2006) Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. Journal of Immunology 176: 3753-3759. PMID: 16517744
51. Castel G, Chteoui M, Heyd B, Tordo N (2011) Phage Display of Combinatorial Peptide Libraries: Application to Antiviral Research. Molecules 16: 3499-3518. doi: 10.3390/molecules16053499 PMID: 21522083
52. Pollard RB, Rockstroh JK, Pantaleo G, Asmuth DM, Peters B, et al. (2014) Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 14: 291-300. doi: 10.1016/S1473-3099(13)70343-8 PMID: 24525316
53. Lockless SW, Ranganathan R (1999) Evolutionarily conserved pathways of energetic connectivity in protein families. Science 286: 295-299. PMID: 10514373
54. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, et al. (1999) NAMD2: Greater scalability for parallel molecular dynamics. Journal of Computational Physics 151: 283-312.
55. Mackerell AD, Feig M, Brooks CL (2004) Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. Journal of Computational Chemistry 25: 1400-1415. PMID: 15185334
56. Buck M, Bouguet-Bonnet S, Pastor RW, MacKerell AD (2006) Importance of the CMAP correction to the CHARMM22 protein force field: Dynamics of hen lysozyme. Biophys J 90: L36-L38. PMID: 16361340
57. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, et al. (2011) Open Babel: An open chemical toolbox. J Cheminform 3: 33. doi: 10.1186/1758-2946-3-33 PMID: 21982300
58. Diller DJ, Merz KM Jr. (2001) High throughput docking for library design and library prioritization. Proteins 43: 113-124. PMID: 11276081
59. Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, et al. (2006) Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nature Structural &Molecular Biology 13: 740-747. PMID: 16862157
60. Hill CP, Worthylake D, Bancroft DP, Christensen AM, SundquistWI (1996) Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly. Proceedings of the National Academy of Sciences of the United States of America 93: 3099-3104. PMID: 8610175
61. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua YZ, Whitby FG, et al. (2009) X-Ray Structures of the Hexameric Building Block of the HIV Capsid. Cell 137: 1282-1292. doi: 10.1016/j.cell.2009.04.063 PMID: 19523676
62. De Guzman RN, Wu ZR, Stalling CC, Pappalardo L, Borer PN, et al. (1998) Structure of the HIV-1 nucleocapsid protein bound to the SL3 Psi-RNA recognition element. Science 279: 384-388. PMID: 9430589
63. Swain AL, Miller MM, Green J, Rich DH, Schneider J, et al. (1990) X-Ray Crystallographic Structure of a Complex between a Synthetic Protease of Human Immunodeficiency Virus-1 and a Substrate-Based Hydroxyethylamine Inhibitor. Proceedings of the National Academy of Sciences of the United States of America 87: 8805-8809. PMID: 2247451
64. Chen JCH, Krucinski J, Miercke LJW, Finer-Moore JS, Tang AH, et al. (2000) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proceedings of the National Academy of Sciences of the United States of America 97: 8233-8238. PMID: 10890912
65. Fossen T, Wray V, Bruns K, Rachmat J, Henklein P, et al. (2005) Solution structure of the human immunodeficiency virus type 1 p6 protein. Journal of Biological Chemistry 280: 42515-42527. PMID: 16234236
66. Arold S, Franken P, Strub MP, Hoh F, Benichou S, et al. (1997) The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 5: 1361-1372. PMID: 9351809
67. Battiste JL, Mao HY, Rao NS, Tan RY, Muhandiram DR, et al. (1996) alpha helix-RNA major groove recognition in an HIV-1 Rev peptide RRE RNA complex. Science 273: 1547-1551. PMID: 8703216
68. Peloponese JM, Gregoire C, Opi S, Esquieu D, Sturgis J, et al. (2000) H-1-C-13 nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. Comptes Rendus De L Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences 323: 883-894.
69. Stanley BJ, Ehrlich ES, Short L, Yu YK, Xiao ZX, et al. (2008) Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. Journal of Virology 82: 8656-8663. doi: 10.1128/JVI.00767-08 PMID: 18562529
70. Wecker K, Morellet N, Bouaziz S, Roques BP (2002) NMR structure of the HIV-1 regulatory protein Vpr in H2O/trifluoroethanol - Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domains. European Journal of Biochemistry 269: 3779-3788. PMID: 12153575
71. Willbold D, Hoffmann S, Rosch P (1997) Secondary structure and tertiary fold of the human immunodeficiency virus protein U (Vpu) cytoplasmic domain in solution. European Journal of Biochemistry 245: 581-588. PMID: 9182993
72. Shafer RW, Schapiro JM (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. Aids Reviews 10: 67-84. PMID: 18615118
73. Poveda E, Soriano V (2006) Resistance to entry inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London.
74. Forssmann WG, The YH, Stoll M, Adermann K, Albrecht U, et al. (2010) Short-Term Monotherapy in HIV-Infected Patients with a Virus Entry Inhibitor Against the gp41 Fusion Peptide. Science Translational Medicine 2. doi: 10.1126/scitranslmed.3001697 PMID: 21532938
75. Agniswamy J, Shen CH, Aniana A, Sayer JM, Louis JM, et al. (2012) HIV-1 Protease with 20 Mutations Exhibits Extreme Resistance to Clinical Inhibitors through Coordinated Structural Rearrangements. Biochemistry 51: 2819-2828. doi: 10.1021/bi2018317 PMID: 22404139